Ginkgo Bioworks (DNA) 10% Owner Barry Canton Sells $418K of Stock

Barry Canton sold 41,172 shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) on October 19, 2026, for a total value of roughly $417,607. According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed at an average price of $10.14 per share. The stock closed at $10.07 on the day of the trade. This sale was not executed under a pre-arranged rule 10b5-1 trading plan.

DNA Ginkgo Bioworks Holdings, Inc.

$10.01 ▲ +15.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Barry Canton's Ginkgo Bioworks Trade

The insider sold the shares in a single transaction on October 19, 2026. Following the trade, Canton held 356,329 shares of the biotech company. This reduction amounted to a 10.36% cut in their total holdings. Ginkgo Bioworks shares traded close to that level during the session, remaining a point of focus as the firm approaches its next financial update.

Other Institutional Activity in Ginkgo Bioworks

Large investors adjusted their positions in the company earlier in the year. Viking Global Investors, L.P. maintained its stake, ending the period with 3,577,128 shares valued at about $35.8 million. Erste Asset Management GmbH grew its holdings by 589,193 shares, a 30.2% increase, ending with 2,536,939 shares worth about $25.4 million. BAILLIE GIFFORD & CO held steady with 2,391,649 shares valued at roughly $23.9 million. Anchorage Capital Group, LLC kept its position unchanged at 1,746,363 shares worth about $17.5 million. Legal & General Group PLC lifted its stake by 7,810 shares, a 0.5% increase, to finish with 1,669,419 shares worth about $16.7 million.

Ginkgo Bioworks Holdings, Inc. Stock Down 1.3%

Ginkgo Bioworks shares recently traded around $9.73 as of October 21, 2026, which is down about 3.4% from the event close on the transaction date. The stock trades above both its 50-day moving average of $8.92 and its 200-day moving average of $8.52. The recent price sits well below its 52-week high of $18.22 while staying higher than its 52-week low of $5.37.

Recent Earnings

Ginkgo Bioworks reported trailing twelve month revenue of $132.4 million and an EPS of negative $5.06. The company registered a negative revenue growth rate of 48.5% year over year. Profitability metrics showed a net margin of negative 219.6% and a return on equity of negative 59.9%. Investors await the company's next earnings report scheduled for November 5, 2026, for further updates on financial performance.

Insider Buying and Selling at Ginkgo Bioworks Holdings, Inc.

Earlier insider transactions included Chief Financial Officer Steven P. Coen selling 752 shares on July 17, 2026, at $7.90 for a total value of $5,943. Coen later sold 330 shares on August 24, 2026, at $6.98 for $2,302. Director Christian O Henry sold 5,000 shares on September 15, 2026, at $7.08 for $35,405. Coen executed another sale of 2,403 shares on October 5, 2026, at $15.00 for $36,045. These followed prior coverage including a purchase by Christian Henry on June 11, 2026, alongside recent sales by CEO Jason R Kelly and President Reshma P. Shetty on October 19, 2026.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock. TD Cowen downgraded the stock to a Hold rating and lowered its price target from $12.00 to $9.00 on August 7, 2026. BTIG reiterated a Sell rating with a $5.00 price target on September 4, 2026. Later, TD Cowen maintained its Hold rating while raising its price target from $9.00 to $11.00 on October 13, 2026. Overall consensus analyst ratings place the stock at underperform with a mean price target of $8.00.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc. operates a platform for cell engineering in the United States and serves clients through its Cell Engineering and Biosecurity segments. The Boston-based company employs 485 people and focuses on biological design automation.

Bottom Line

Barry Canton's recent share sale reduces their personal exposure to the company by about 10%. Investors will watch the upcoming earnings release on November 5, 2026, for any signs of progress in the firm's cell engineering operations.